相关实验视频

Updated: Jun 27, 2026

Shrinkage of Dental Composite in Simulated Cavity Measured with Digital Image Correlation
08:45

Shrinkage of Dental Composite in Simulated Cavity Measured with Digital Image Correlation

Published on: July 21, 2014

13.6K

作为后部恢复的单色树脂复合物的临床性能:一个随机对照临床试验

Ruba Salah Anwar1, Yasser Fathi Hussein2, Mona Riad3

  • 1Conservative Dentistry Department, Faculty of Dentistry, Minia University, Minya, Egypt.

Scientific reports
|July 12, 2025
PubMed
概括

单色通用树脂复合材料在12个月的后部修复中显示出令人满意的临床性能. 它为多色复合材料提供了可行的替代品,特别是当椅子上的时间至关重要时.

关键词:
颜色匹配和稳定性的一致性.经过修改的USPHS.聚阴影纳米混合树脂复合材料树脂复合材料具有麻雀效果的树脂复合材料.

更多相关视频

Detection and Removal of Tooth-Colored Composite Resin Using the Fluorescence-Aided Identification Technique05:42

Detection and Removal of Tooth-Colored Composite Resin Using the Fluorescence-Aided Identification Technique

Published on: July 27, 2022

3.8K
Quasistatic Mechanical Testing for Computer-Aided Design and Manufacturing Occlusal Veneers Cemented to Milled Dentin Analog Material07:42

Quasistatic Mechanical Testing for Computer-Aided Design and Manufacturing Occlusal Veneers Cemented to Milled Dentin Analog Material

Published on: December 20, 2024

463

相关概念视频

Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Drug Product Performance: In Vitro–In Vivo Correlation01:20

Drug Product Performance: In Vitro–In Vivo Correlation

In pharmaceutical development, it's crucial to establish a predictive in vitro–in vivo correlation (IVIVC) for two or more formulations to gain a comprehensive understanding of release properties. IVIVC reduces the need for costly in vivo studies and facilitates the establishment of meaningful dissolution specifications with significant cost savings and decreased regulatory burden. Furthermore, a meaningful IVIVC should predict Cmax and AUC within 20%, aligning with FDA guidance while adhering...
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence01:22

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence01:27

Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...